Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

Eichenauer, Dennis A.; Plütschow, Annette; Kreissl, Stefanie; Sökler, Martin; Hellmuth, Johannes C.; Meißner, Julia; Mathas, Stephan; Topp, Max S.; Behringer, Karolin; Klapper, Wolfram; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Fuchs, Michael; Diehl, Volker; Engert, Andreas; Borchmann, Peter

doi:10.1016/s1470-2045(17)30696-4

Cited by 104 publications

(79 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Phase 2 trials of checkpoint inhibitors, specifically nivolumab and pembrolizumab, have shown outstanding efficacy in adults with relapsed/refractory HL leading to their Food and Drug Administration (FDA) approval for these indications. The anti‐CD30 antibody–drug conjugate brentuximab vedotin (Bv) has shown efficacy in adults in both relapsed and up‐front settings . The combination of Bv with gemcitabine demonstrated high complete response rates in patients up to age 30 with relapsed/refractory HL …”

Section: Treatmentmentioning

confidence: 99%

“…The anti-CD30 antibody-drug conjugate brentuximab vedotin (Bv) has shown efficacy in adults in both relapsed and upfront settings. 45,46 The combination of Bv with gemcitabine demonstrated high complete response rates in patients up to age 30 with relapsed/refractory HL. 47,48 Ongoing studies include a Phase 2 study investigating Bv in place of vincristine in the OEPA/COPDac regimen (NCT01920932) and Sequential randomized clinical trials in HL have led to steady improvements in disease-related survival and continued reductions in therapy-related toxicities.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care

Kahn

Kelly

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) is one of the most common cancers in the adolescent and young adult (AYA) population (15-39 years). Despite continued improvements in HL outcomes, AYAs have not exhibited survival gains to the same extent as other age groups. At present, details about tumor biology, optimal therapeutic approaches, supportive care needs, and long-term toxicities in AYAs with HL remain understudied. Herein, we summarize the current state of the AYA population with HL, specifically focusing on how collaborations across the pediatric and medical oncology divide, coupled with multidisciplinary patient care, can further optimize outcomes for this group of patients.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care

Kahn

Kelly

2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Meanwhile, German Hodgkin Study Group incorporated BV in BEACOPPesc resulting in hybrid regimens BrECAPP and BrECADD on 104 subjects. 5 Dosage of brentuximab vedotin was 1.8 mg/kg every 3 weeks. Concerning safety profile, grade IV hematologic toxicities were prominent occurring in 80% and 79% based on randomization, but BrECADD regimen had negligible organ-related toxicity.…”

Section: Introductionmentioning

confidence: 99%

FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

Milunović

Jakobac

Kursar

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

ECHELON-1 study is a randomized open-labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow-up of 24.6 months, it has met its primary endpoint the reduction of modified progression-free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in-depth insight of pros and cons of this novel, promising but ultimately controversial regimen. K E Y W O R D Sbrentuximab vedotin, Hodgkin lymphoma, induction chemotherapy, monoclonal antibodies

show abstract

“…To reduce short‐ and long‐term toxicity of BEACOPP escalated or improve efficacy of ABVD, variants of the regimens incorporating novel agents, such as the anti‐CD30 antibody‐drug conjugate brentuximab vedotin (BV) or the anti‐PD1 antibody nivolumab, are under investigation. Results of the randomized phase III ECHELON‐1 trial with BV‐AVD versus ABVD and a phase II trial investigating BV‐based BEACOPP variants were recently reported (Ansell et al , ; Connors et al , ; Eichenauer et al , ).…”

mentioning

confidence: 99%

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

Bröckelmann

McMullen²,

Wilson³

et al. 2018

Br J Haematol

View full text Add to dashboard Cite

Summary First‐line treatments for classical Hodgkin lymphoma ( HL ) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPP escalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography‐driven strategies and ABVD or BEACOPP variants incorporating the antibody‐drug conjugate brentuximab vedotin ( BV ) or anti‐ PD 1 antibodies are under investigation in advanced‐stage patients. The present study aimed to elicit preferences for attributes associated with ABVD , BEACOPP escalated and BV ‐ AVD ( BV , adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross‐sectional online discrete choice experiments were administered to HL patients ( n = 381) and haematologists/oncologists ( n = 357) in France, Germany and the United Kingdom. Included attributes were progression‐free survival ( PFS ), overall survival ( OS ), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5‐year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians’ recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians’ treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.

show abstract

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

Cited by 104 publications

References 21 publications

Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care

Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care

FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

Contact Info

Product

Resources

About